{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:50:34Z","timestamp":1791831034775,"version":"4.3.4"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>An association between proton pump inhibitor (PPI) use and hip fracture risk has been described in the general population, where the primary causative hypothesis focuses on impaired gastrointestinal calcium absorption. The impact of acid suppressor use on hip fracture risk in a high-risk subset, patients with ESKD requiring hemodialysis, is unknown and could help further distinguish the reason for higher susceptibility among PPI users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Using the US Renal Data System, we identified all hip fracture events recorded between 2009 and 2014 among patients dependent on hemodialysis. Eligible cases were matched on index date with ten controls. We identified PPI and histamine-2 receptor antagonist use from Medicare Part D claims covering 3 years before the index date and stratified according to proportion of days covered by filled prescriptions. Using logistic regression with multiple imputation for missing data, we estimated unadjusted and multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We studied 4551 cases and 45,510 controls. Patients were older, more likely to be female and white, and had shorter dialysis vintage; fewer were obese. A larger proportion of patients had any prior PPI (70% versus 63%) or histamine-2 receptor antagonist (25% versus 23%) use. Use of PPI was associated with higher risk of hip fracture (adjusted OR, 1.19; 95% CI, 1.11 to 1.28). This association remained within subgroups of low, moderate, and high PPI use, yielding adjusted ORs of 1.16 (95% CI, 1.06 to 1.27), 1.21 (95% CI, 1.11 to 1.31), and 1.19 (95% CI, 1.08 to 1.31), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with ESKD on hemodialysis, PPIs and not histamine-2 receptor antagonists were associated with hip fracture events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.02190218","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T11:16:37Z","timestamp":1538046997000},"page":"1534-1541","source":"Crossref","is-referenced-by-count":19,"title":["Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis"],"prefix":"10.2215","volume":"13","author":[{"given":"Chandan","family":"Vangala","sequence":"first","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine, Houston, Texas;"},{"name":"Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Niu","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R.","family":"Lenihan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Stanford University School of Medicine, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Mitch","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine, Houston, Texas;"},{"name":"Division of Nephrology, Michael E. DeBakey VA Medical Center, Houston, Texas; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5272-425X","authenticated-orcid":false,"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Baylor College of Medicine, Houston, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1053\/j.ajkd.2013.02.368","article-title":"Trends in hip fracture rates in US hemodialysis patients, 1993-2010.","volume":"62","author":"Arneson","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0272-6386(04)00958-8","article-title":"Increased risk of mortality associated with hip fracture in the dialysis population.","volume":"44","author":"Mittalhenkle","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.10901012","article-title":"Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States.","volume":"8","author":"Nair","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1681\/ASN.2012090916","article-title":"Temporal trends in fracture rates and postdischarge outcomes among hemodialysis patients.","volume":"24","author":"Beaubrun","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: An update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture.","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1172\/JCI111254","article-title":"An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.","volume":"73","author":"Bo-Linn","year":"1984","journal-title":"J Clin Invest"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/07315724.1995.10718522","article-title":"Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.","volume":"14","author":"Serfaty-Lacrosniere","year":"1995","journal-title":"J Am Coll Nutr"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/00365529409092460","article-title":"Growth of the parathyroid glands in omeprazole-treated chickens.","volume":"29","author":"Gagnemo-Persson","year":"1994","journal-title":"Scand J Gastroenterol"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1111\/febs.12478","article-title":"Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.","volume":"280","author":"Costa-Rodrigues","year":"2013","journal-title":"FEBS J"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.","volume":"139","author":"Corley","year":"2010","journal-title":"Gastroenterology"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bone.2010.12.015","article-title":"Meta-analysis: Risk of fractures with acid-suppressing medication.","volume":"48","author":"Kwok","year":"2011","journal-title":"Bone"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"issue":"Suppl 1","key":"B15-20230813","first-page":"S1","article-title":"US renal data system 2015 annual data report: Epidemiology of kidney disease in the United States.","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/EDE.0b013e318227af1a","article-title":"Pooled exposure assessment for matched case-control studies.","volume":"22","author":"Saha-Chaudhuri","year":"2011","journal-title":"Epidemiology"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.0006-341X.1999.00718.x","article-title":"Using pooled exposure assessment to improve efficiency in case-control studies.","volume":"55","author":"Weinberg","year":"1999","journal-title":"Biometrics"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/jama.2009.1463","article-title":"Cardiovascular diseases and risk of hip fracture.","volume":"302","author":"Sennerby","year":"2009","journal-title":"JAMA"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1161\/CIRCULATIONAHA.108.820993","article-title":"Peripheral arterial disease is associated with higher rates of hip bone loss and increased fracture risk in older men.","volume":"119","author":"Collins","year":"2009","journal-title":"Circulation"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/bmj.315.7112.841","article-title":"A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: Recognition of a major effect.","volume":"315","author":"Law","year":"1997","journal-title":"BMJ"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/JOE-08-0568","article-title":"Bone loss in inflammatory disorders.","volume":"201","author":"Hardy","year":"2009","journal-title":"J Endocrinol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2215\/CJN.01650506","article-title":"Falls and fall-related injuries in older dialysis patients.","volume":"1","author":"Cook","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.2105\/AJPH.79.11.1556","article-title":"Geographic variation in the occurrence of hip fractures among the elderly white US population.","volume":"79","author":"Bacon","year":"1989","journal-title":"Am J Public Health"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"865.e1","DOI":"10.1016\/j.jamda.2016.06.012","article-title":"Geographic variation in hip fracture among United States longstay nursing home residents.","volume":"17","author":"Banerjee","year":"2016","journal-title":"J Am Med Dir Assoc"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2215\/CJN.10141013","article-title":"Addressing missing data in clinical studies of kidney diseases.","volume":"9","author":"Montez-Rath","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","article-title":"Multiple imputation of discrete and continuous data by fully conditional specification.","volume":"16","author":"van Buuren","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1756283X16650156","article-title":"Use of proton-pump inhibitors among adults: A Danish nationwide drug utilization study.","volume":"9","author":"Potteg\u00e5rd","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"B31-20230813","first-page":"322","article-title":"Long-term use of proton-pump inhibitor therapy.","volume":"4","author":"Metz","year":"2008","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jbmr.2344","article-title":"Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: A SWAN cohort study.","volume":"30","author":"Solomon","year":"2015","journal-title":"J Bone Miner Res"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","article-title":"Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.","volume":"138","author":"Targownik","year":"2010","journal-title":"Gastroenterology"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/jcb.23337","article-title":"Decreased bone mineral density and reduced bone quality in H(+) \/K(+) ATPase beta-subunit deficient mice.","volume":"113","author":"Fossmark","year":"2012","journal-title":"J Cell Biochem"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01352010","article-title":"Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans.","volume":"53","author":"Mizunashi","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"607","DOI":"10.5009\/gnl14135","article-title":"A proton pump inhibitor\u2019s effect on bone metabolism mediated by osteoclast action in old age: A prospective randomized study.","volume":"9","author":"Jo","year":"2015","journal-title":"Gut Liver"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial.","volume":"118","author":"O\u2019Connell","year":"2005","journal-title":"Am J Med"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1525-1594.1998.06200.x","article-title":"Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis.","volume":"22","author":"Hardy","year":"1998","journal-title":"Artif Organs"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients.","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1681\/ASN.2017080849","article-title":"Magnesium and risk of hip fracture among patients undergoing hemodialysis.","volume":"29","author":"Sakaguchi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2012.452","article-title":"Proton-pump inhibitor use is associated with low serum magnesium concentrations.","volume":"83","author":"Danziger","year":"2013","journal-title":"Kidney Int"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/j.ajkd.2015.05.012","article-title":"Proton pump inhibitors and hypomagnesemia in the general population: A population-based cohort study.","volume":"66","author":"Kieboom","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/hdi.12437","article-title":"Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study.","volume":"20","author":"Ago","year":"2016","journal-title":"Hemodial Int"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"e0143656","DOI":"10.1371\/journal.pone.0143656","article-title":"Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: A cross-sectional study.","volume":"10","author":"Nakashima","year":"2015","journal-title":"PLoS One"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000360011","article-title":"Hypomagnesemia in hemodialysis patients: Role of proton pump inhibitors.","volume":"39","author":"Alhosaini","year":"2014","journal-title":"Am J Nephrol"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12882-015-0139-9","article-title":"The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: A cross-sectional study.","volume":"16","author":"Misra","year":"2015","journal-title":"BMC Nephrol"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2044.2008.05861.x","article-title":"The effect of ranitidine versus proton pump inhibitors on gastric secretions: A meta-analysis of randomised control trials.","volume":"64","author":"Clark","year":"2009","journal-title":"Anaesthesia"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1440-1797.2012.01583.x","article-title":"Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: A pilot study.","volume":"17","author":"Lai","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1797.2012.01604.x","article-title":"Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.","volume":"17","author":"Cervelli","year":"2012","journal-title":"Nephrology (Carlton)"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/bdd.532","article-title":"Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects.","volume":"28","author":"Palaparthy","year":"2007","journal-title":"Biopharm Drug Dispos"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:41Z","timestamp":1786369121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201810000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.02190218","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]}}}